Bruker Corp filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-04-10. Between them they name 1 person, with 1 appointment and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Reported
On April 6, 2026, Bruker Corporation (the "Company") and Falko Busse, Ph.D., an executive officer of the Company and President of the Bruker BioSpin Group ("Bruker BioSpin"), a wholly owned subsidiary of the Company, agreed that his duties as executive officer with the Company and as President of Bruker BioSpin would transition on or around May 1, 2026 and that his employment with the Company and Bruker BioSpin would terminate as of October 31, 2026 (the "Separation Date").
Appointed: Thierry L. Bernard, Director, effective 2026-04-01
(d) Election of New Director On March 27, 2026, the Board of Directors (the "Board") of Bruker Corporation (the "Company") approved an increase in the number of directors to expand the size of the Board by one director to a total of twelve directors, with such additional director assigned to Class III, and appointed Thierry L. Bernard to fill the newly created vacancy on the Board, effective as of April 1, 2026.
Departing: Thierry L. Bernard
In November 2025, QIAGEN announced a CEO transition plan whereby Mr. Bernard will step down as CEO and Managing Director once his successor is appointed.
Find people with the same kind of experience as the Director at Bruker Corp, with the record behind each one.
Find candidates like Director at Bruker CorpNew leaders review vendors and budgets in their first months. Get an alert the next time Bruker Corp is in the news or changes leadership.
Get an alert when Bruker Corp changes leadershipTools for this story
Each opens in a new tab, filled in for Bruker Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.